KR20230148156A - 비알코올성 지방간 질병 및 관련 질병 또는 장애를치료 또는 개선하기 위한 화합물, 조성물, 및 방법 - Google Patents
비알코올성 지방간 질병 및 관련 질병 또는 장애를치료 또는 개선하기 위한 화합물, 조성물, 및 방법 Download PDFInfo
- Publication number
- KR20230148156A KR20230148156A KR1020237027597A KR20237027597A KR20230148156A KR 20230148156 A KR20230148156 A KR 20230148156A KR 1020237027597 A KR1020237027597 A KR 1020237027597A KR 20237027597 A KR20237027597 A KR 20237027597A KR 20230148156 A KR20230148156 A KR 20230148156A
- Authority
- KR
- South Korea
- Prior art keywords
- subject
- sigma1
- expression
- sigmar1
- nash
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163137915P | 2021-01-15 | 2021-01-15 | |
| US63/137,915 | 2021-01-15 | ||
| PCT/US2022/012516 WO2022155471A1 (en) | 2021-01-15 | 2022-01-14 | Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230148156A true KR20230148156A (ko) | 2023-10-24 |
Family
ID=82448695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237027597A Pending KR20230148156A (ko) | 2021-01-15 | 2022-01-14 | 비알코올성 지방간 질병 및 관련 질병 또는 장애를치료 또는 개선하기 위한 화합물, 조성물, 및 방법 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240307325A1 (https=) |
| EP (1) | EP4277898A4 (https=) |
| JP (1) | JP2024504632A (https=) |
| KR (1) | KR20230148156A (https=) |
| CA (1) | CA3204756A1 (https=) |
| WO (1) | WO2022155471A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116942821A (zh) * | 2023-06-02 | 2023-10-27 | 深圳市第二人民医院(深圳市转化医学研究院) | Sigmar1基因抑制剂在制备治疗或预防脂肪肝病的药物中的应用 |
| WO2025194019A1 (en) * | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Methods for treating liver fibrosis and non-alcoholic fatty liver disease |
| WO2026057679A1 (en) * | 2024-09-11 | 2026-03-19 | Institut National de la Santé et de la Recherche Médicale | Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130142861A1 (en) * | 2011-12-05 | 2013-06-06 | National Yang Ming University | Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis |
| WO2014015157A2 (en) * | 2012-07-19 | 2014-01-23 | Philadelphia Health & Education Corporation | Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
| WO2018112122A1 (en) * | 2016-12-16 | 2018-06-21 | Drexel University | Methods of identifying and treating tumors with sigma1 inhibitors |
| EP3745862B1 (en) * | 2018-01-31 | 2024-06-26 | Mayo Foundation for Medical Education and Research | D1 dopamine receptor agonists for treating fibrotic pathologies |
| WO2020112846A1 (en) * | 2018-11-27 | 2020-06-04 | Northwestern University | Small molecule modulators of sigma-1 and sigma-2 receptors and uses thereof |
-
2022
- 2022-01-14 CA CA3204756A patent/CA3204756A1/en active Pending
- 2022-01-14 US US18/272,486 patent/US20240307325A1/en active Pending
- 2022-01-14 WO PCT/US2022/012516 patent/WO2022155471A1/en not_active Ceased
- 2022-01-14 KR KR1020237027597A patent/KR20230148156A/ko active Pending
- 2022-01-14 JP JP2023542860A patent/JP2024504632A/ja active Pending
- 2022-01-14 EP EP22740146.0A patent/EP4277898A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3204756A1 (en) | 2022-07-21 |
| EP4277898A4 (en) | 2024-12-11 |
| EP4277898A1 (en) | 2023-11-22 |
| WO2022155471A1 (en) | 2022-07-21 |
| JP2024504632A (ja) | 2024-02-01 |
| US20240307325A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020216186C1 (en) | Oligonucleotide compositions and methods thereof | |
| US10159670B2 (en) | Methods of diagnosing and treating motor neuron diseases and other cellular stress-related diseases | |
| KR102638276B1 (ko) | 인트론 잔류의 감소 | |
| JP5535076B2 (ja) | 肝臓癌を治療するための標的化ミクロrna | |
| KR20230148156A (ko) | 비알코올성 지방간 질병 및 관련 질병 또는 장애를치료 또는 개선하기 위한 화합물, 조성물, 및 방법 | |
| KR20190027373A (ko) | 유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드 | |
| US12077527B2 (en) | Compositions and methods for inhibiting ACSS2 | |
| KR20140033062A (ko) | 마이크로rna 화합물 및 mir-21 활성 조절 방법 | |
| CN118369427A (zh) | 肝外递送irna组合物及其使用方法 | |
| US20220064642A1 (en) | Oligomeric nucleic acid molecule and application thereof | |
| KR20050050111A (ko) | 전립선암 및 다른 암의 치료 방법 및 조성물 | |
| EP2475367A1 (en) | NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES | |
| JP2016510327A (ja) | p53再活性化のためのオリゴオキソピペラジン | |
| WO2022026648A1 (en) | Inhibition of incexact1 to treat heart disease | |
| KR102185966B1 (ko) | Otub1 억제제를 유효성분으로 함유하는 항암 약제의 항암 효과 증진용 약학 조성물 및 이를 이용한 항암 효과 증진방법 | |
| CN114729363A (zh) | Il-34反义剂及其使用方法 | |
| WO2025054596A2 (en) | Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto | |
| KR20070088706A (ko) | 암세포 특이적 세포증식 억제제 | |
| WO2023097251A1 (en) | Oligonucleotide-containing transcription factor targeting chimeras | |
| US20190055553A1 (en) | Methods for identifying and targeting non-coding rna scaffolds | |
| WO2015077693A2 (en) | Use of microrna 146-a in the diagnosis, treatment and prevention of picornavirus infection and microran 146-a antagonists | |
| WO2024076967A1 (en) | Compositions and methods for treating or preventing nonalcoholic steatohepatitis (nash), anorexia, depression, endometriosis, and other diseases or disorders | |
| US20250375465A1 (en) | Methods for affecting tissue-resident t cells | |
| RU2847121C2 (ru) | Композиции на основе олигонуклеотидов и способы, связанные с ними | |
| CN109136224A (zh) | miR-221/222及其抑制剂用于制备调控肝脂肪沉积、肝纤维化和肝细胞癌的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230814 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20241227 Comment text: Request for Examination of Application |